Enhanced efficacy of the engineered antimicrobial peptide WLBU2 via direct airway delivery in a murine model of P. aeruginosa pneumonia

摘要

ObjectivesP. aeruginosa is a common cause of pneumonia in cystic fibrosis patients with the property to generate multidrug resistance against clinically used antibiotics. Antimicrobial peptides (AMPs) are a diverse group of effector molecules of the innate immunity that protect the host against pathogens. However, the lack of activity in common biological matrices has hampered efforts towards clinical development. In this study, we evaluated the therapeutic potential of engineered antimicrobial peptide WLBU2 via direct airway delivery in a murine model of P. aeruginosa infection.